Intellia Therapeutics

Yahoo Finance • 2 days ago

Intellia Therapeutics Announces Positive Longer-Term Phase 1 Data for Nexiguran Ziclumeran (nex-z) in Patients with Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy

One dose of nex-z led to rapid, deep and durable TTR reductions, with mean reductions of at least 90% from baseline sustained through three yearsStabilization or improvement in disease-related clinical measures observed at 24 monthsContinu... Full story

Yahoo Finance • 5 days ago

Intellia Therapeutics to Present Longer-Term Data from the Ongoing Phase 1 Clinical Trial of Nexiguran Ziclumeran (nex-z) for the Treatment of Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy

CAMBRIDGE, Mass., Sept. 22, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that longer-te... Full story

Yahoo Finance • 9 days ago

Intellia Therapeutics Completes Enrollment in the Global Phase 3 HAELO Study of Lonvoguran Ziclumeran (lonvo-z) for Hereditary Angioedema

Completed patient enrollment within nine months with nearly half enrolled from the U.S.Expect to report Phase 3 topline data in the first half of 2026On track to submit BLA in the second half of 2026 for an anticipated U.S. launch in the f... Full story

Yahoo Finance • 22 days ago

Cathie Wood’s Ark Invest buys the dip in Figma as stock sinks ~20%

[Bitcoin 2022 Conference Draws Cryptocurrency Industry Professionals And Investors To Miami] Marco Bello/Getty Images News Cathie Wood’s investment manager Ark Invest has bought over 100K shares of Figma (NYSE:FIG [https://seekingalpha.co... Full story

Yahoo Finance • 25 days ago

Tesla's India Dream Hits a Wall: Just 600 Orders, While BYD Doubles Down

This article first appeared on GuruFocus. Tesla (NASDAQ:TSLA) may have entered India with brand swagger and long-term ambition, but the initial numbers tell a more muted story. Since launching sales in mid-July, the company has received j... Full story

Yahoo Finance • last month

Cathie Wood's ARK buys CRISPR, sells Roku and DraftKings stock

Cathie Wood’s ARK ETFs have reported their daily trades for Tuesday, August 26th, 2025, with significant activity in biotech and tech stocks. The largest trade of the day was the purchase of 165,874 shares of CRISPR THERAPEUTICS AG (NASDAQ... Full story

Yahoo Finance • last month

Cathie Wood's ARK shifts focus, buys CRSP stock, sells ROKU

Cathie Wood’s ARK ETF released their daily trades for Monday, August 25th, 2025, revealing a significant reshuffle in their portfolio. The firm’s largest transaction involved selling 141,194 shares of Roku Inc (NASDAQ:ROKU), amounting to a... Full story

Yahoo Finance • last month

Monday 8/25 Insider Buying Report: NTLA, INR

Bargain hunters are wise to pay careful attention to insider buying, because although there are many various reasons for an insider to sell a stock, presumably the only reason they would use their hard-earned dollars to make a purchase, is... Full story

Yahoo Finance • last month

Cathie Wood's ARK ETF adjusts portfolio with PagerDuty and Robinhood stock trades

Cathie Wood’s ARK ETFs have published their daily trades for Thursday, 21 August 2025, unveiling a series of strategic buy and sell moves in the tech and biotech sectors. The most significant transaction of the day was the purchase of 138,... Full story

Yahoo Finance • last month

Attack Surface Management Market Surges to $3.3 billion by 2029 - Dominated by Palo Alto Networks (US), IBM(US), Microsoft (US)

Delray Beach, FL, Aug. 21, 2025 (GLOBE NEWSWIRE) -- According to MarketsandMarkets™, the Attack Surface Management Market estimated value stands at USD 0.9 billion in 2024, with projections indicating it could soar to USD 3.3 billion by... Full story

Yahoo Finance • last month

ARK Investment buys 560K shares of Intellia Therapeutics

* Cathie Wood's ARK Investment has purchased 560,600 shares of biotech and gene editing company Intellia Therapeutics (NASDAQ:NTLA [https://seekingalpha.com/symbol/NTLA]). * The stock has a Seeking Alpha quant rating of Hold, [https://... Full story

Yahoo Finance • last month

Cathie Wood's ARK ETF bolsters biotech, trims defense stock

Cathie Wood’s ARK ETF published their daily trades for Monday, August 18th, 2025, showcasing a continued focus on the biotech sector while reducing exposure in defense. The largest trade of the day was the purchase of 170,471 shares of Gen... Full story

Yahoo Finance • last month

Intellinum™ Launches FlexiPro™ Mobile Service Inventory: Mobile Inventory Management for Field Operations

DALLAS, Aug. 18, 2025 /PRNewswire/ -- Intellinum, Oracle's preferred mobility partner and global leader in logistics and supply chain mobility, is proud to announce the launch of FlexiPro Mobile Service Inventory™ (MSI)—a purpose-built mob... Full story

Yahoo Finance • last month

Cathie Wood's ARK ETF focuses on Roblox and CoreWeave stock buys

Cathie Wood’s ARK ETF released its daily trades for Friday, August 15th, 2025, revealing a series of strategic investments and divestments across various sectors. The largest transaction of the day was the purchase of 125,799 shares of Rob... Full story

Yahoo Finance • last month

Europe Battery Energy Storage System Market Forecast and Company Analysis Report 2025-2033 Featuring CATL, Fluence Energy, Tesla, BYD, LG Energy, Samsung, Wartsila, Northvolt, Saft Groupe, Panasonic

Company Logo The Europe Battery Energy Storage System (BESS) Market is projected to soar from US$ 18.1 billion in 2024 to US$ 87.34 billion by 2033, marking a CAGR of 19.11%. This surge is driven by increased renewable energy adoption, su... Full story

Yahoo Finance • last month

Intellia Therapeutics stock price target slashed by Guggenheim to $14

Investing.com - Guggenheim lowered its price target on Intellia Therapeutics (NASDAQ:NTLA) to $14.00 from $45.00 on Wednesday, while maintaining a Buy rating on the gene editing company. According to InvestingPro data, the stock currently... Full story

Yahoo Finance • 2 months ago

Intellia Therapeutics Inc (NASDAQ:NTLA) Q2 2025 Earnings: Revenue Surpasses Estimates, Losses Narrower Than Expected

INTELLIA THERAPEUTICS INC (NASDAQ:NTLA [https://www.chartmill.com/stock/quote/NTLA/profile]) REPORTS Q2 2025 EARNINGS: REVENUE BEATS ESTIMATES, LOSSES NARROWER THAN EXPECTED Intellia Therapeutics, a clinical-stage gene editing company, re... Full story

Yahoo Finance • 2 months ago

Intellia Therapeutics Q2 2025 Earnings Preview

* Intellia Therapeutics (NASDAQ:NTLA [https://seekingalpha.com/symbol/NTLA]) is scheduled to announce Q2 earnings results on Thursday, August 7th, before market open. * The consensus EPS Estimate is -$1.01 [https://seekingalpha.com/sym... Full story

Yahoo Finance • 2 months ago

Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2025 Earnings and Company Updates

CAMBRIDGE, Mass., July 31, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, will present its second quarter... Full story

Yahoo Finance • 3 months ago

The Next Moderna? This Clinical-Stage Biotech Has Breakout Potential.

Doctor holding money by IherPhoto via iStock Moderna (MRNA), an undervalued name in the biotech space, rose to prominence during the COVID-19 pandemic. This occurred when its mRNA-based COVID-19 vaccine was one of the first to be granted... Full story